We are delighted to announce that we are showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report. The report illustrates
Cell4Pharma enters supply agreement with CN Bio
Today, we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalized Renal Proximal Tubule
CN Bio MicroMix to be featured at AACR
Dr David Hughes, Chief Technical Officer at Organ-on-Chip specialist CN Bio Innovations will be presenting a poster at the American Association for
PharmaVentures interview: Will Organ-on-Chip technology provide the data regulators need in the future?
As new drug treatments are developed, quicker and much more precise technology which predicts the effect these chemical and biological substances have
R&D 100 Award won by Vanderbilt team for tech being developed with CN Bio
A cell-culture technology now being developed by London biotech CN Bio Innovations and its global pharmaceutical company partner, has won one of the
MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress
MIT and CN Bio Innovations today announced that the world’s first 7-organ “Human-on-a-Chip” platform will be showcased at the Organ-on-Chip congress
CN Bio Sponsors the Organ-On-Chip world congress in Boston
CN Bio Innovations Ltd, an expert in developing human organs-on-chips to test and develop therapeutics for serious diseases, is proud to be the
CN Bio appoints Emma Sceats as CEO
CN Bio Innovations are delighted to announce the appointment of Dr Emma Sceats as Chief Executive effective 1st January 2016. Dr David Scales will
Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting
New advances in the pre-clinical evaluation of Hepatitis B therapies Welwyn Garden City, UK, 2 Nov 2015: CN Bio Innovations Ltd, an expert in